Clinical Trials Directory

Trials / Completed

CompletedNCT01861067

LESS-TLH Versus LESS-LAVH

A Randomized Comparison of Laparoendoscopic Single-site (LESS) Hysterectomies: Total Laparoscopic Hysterectomy (TLH) Versus Laparoscopically Assisted Vaginal Hysterectomy (LAVH)

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
76 (actual)
Sponsor
CHA University · Academic / Other
Sex
Female
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

During the last 2 decades, several studies have tried to define the best surgical approach to hysterectomy for benign uterine diseases1. Accumulating evidence demonstrates that abdominal hysterectomy has a higher incidence of complications, a longer hospital stay and a slower convalescence in comparison with laparoscopic hysterectomy (LH). The main advantage of LHs is the absence of a wide abdominal scar, which results in fewer wound-related complications and in a significant decrease of postoperative pain. Technologic advances in endoscopic instrumentation and optics have allowed the development of an even less invasive procedure than conventional LH using multiple ports: laparoendoscopic single-site (LESS) surgery, also known as single-port access (SPA) laparoscopy3. In the LESS approaches, total laparoscopic hysterectomy (TLH) and laparoscopically-assisted vaginal hysterectomy (LAVH) are all feasible, with comparable conventional LH. However, it is yet to be determined which of two alternative and less invasive approaches (LESS-TLH and LESS-LAVH) should be preferred. In particular, none has focused on postoperative pain as the primary outcome of the study. The investigators have therefore designed the randomized trial to investigate specifically differences in postoperative pain after LESS-TLH and LESS-LAVH.

Conditions

Interventions

TypeNameDescription
PROCEDURELESS-TLH
PROCEDURELESS-LAVH

Timeline

Start date
2013-04-01
Primary completion
2014-01-01
Completion
2014-01-01
First posted
2013-05-23
Last updated
2015-04-16

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01861067. Inclusion in this directory is not an endorsement.